PatientsVille.com Logo

INFLUENZA and Codeine

PatientsVille

INFLUENZA Symptoms and Causes

Flu is a respiratory infection caused by a number of viruses. The viruses pass through the air and enter your body through your nose or mouth. Between 5% and 20% of people in the U.S. get the flu each year. The flu can be serious or even deadly for elderly people, newborn babies, and people with certain chronic illnesses.

Symptoms of the flu come on suddenly and are worse than those of the common cold. They may include

  • Body or muscle aches
  • Chills
  • Cough
  • Fever
  • Headache
  • Sore throat

Is it a cold or the flu? Colds rarely cause a fever or headaches. Flu almost never causes an upset stomach. And "stomach flu" isn't really flu at all, but gastroenteritis.

Most people with the flu recover on their own without medical care. People with mild cases of the flu should stay home and avoid contact with others, except to get medical care. If you get the flu, your health care provider may prescribe medicine to help your body fight the infection and lessen symptoms.

The main way to keep from getting the flu is to get a yearly flu vaccine. Good hygiene, including hand washing, can also help.

NIH: National Institute of Allergy and Infectious Diseases

Check out the latest treatments for INFLUENZA

INFLUENZA treatment research studies

Codeine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Codeine Side Effects

Toxicity To Various Agents (77)
Vomiting (51)
Nausea (42)
Overdose (33)
Completed Suicide (32)
Rash (27)
Abdominal Discomfort (22)
Death (21)
Pancreatitis Acute (18)
Pruritus (17)
Constipation (16)
Cardiac Arrest (16)
Dizziness (16)
Headache (16)
Serotonin Syndrome (15)
Respiratory Arrest (15)
Accidental Overdose (15)
Hypersensitivity (14)
Malaise (13)
Respiratory Depression (13)
Hallucination (13)
Dyspnoea (13)
Confusional State (12)
Somnolence (12)
Chest Pain (11)
Depression (11)
Abdominal Pain Upper (11)
Urticaria (11)
Hypotension (11)
Poisoning (11)
Pain (11)
Coma (10)
Diarrhoea (10)
Accidental Poisoning (10)
Fatigue (9)
Agitation (9)
Syncope (9)
Intentional Overdose (8)
Fall (8)
Pneumonia (8)
Substance Abuse (8)
Pyrexia (8)
Unresponsive To Stimuli (8)
Arthralgia (7)
Anaphylactic Reaction (7)
Convulsion (7)
Hypokalaemia (7)
Oedema Peripheral (7)
Loss Of Consciousness (7)
Feeling Abnormal (7)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<b>Describe Your Diplopia from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here:</b> In late winter of 2010 I had the regular flu shot and then the H1N1 shot about two days later. I normally wouldn't hav

<span style='color: #808080;'><b>Describe Your Pericarditis from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: Received H1N1 vaccine mid October 2009. Three weeks later diagnosed with accute paricarditis. My age is

<span style='color: #808080;'>i took dihydracodine and got great painless hours after a serious motorcycle accident , i wont go into details and bore you ,<span style='text-decoration: underline;'>i am now on methadone for life,<strong

I feel quite spaced out i was given it today after an painfull extraction each tablet is 30mg and i have taken two

Iwas given dihydrocodeine after being in hospital with tonsillitis that progressed into glandular fever. After my first dose of Dihydrocodeine i felt spaced out and was staring at the ceiling laughing. I am unsure if I was supposed to be pr

Is there such a thing as muscular Influenza and if so how long does it tend to last?

Ive been vaccinated with fluarix 2010/2011 last thursday and got severe muscle pain since saturday.......should i take something to relieve the pain?????

My boyfriend has just taken 800mg ibuprofen, 150mg of dihydrocodeine, 1000mg of paracetomol and drank alcohol. Will he be ok? his blood pressure is 160/109 pulse 66 resp 12

&lt;b&gt;Describe Your Diplopia from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here:&lt;/b&gt; In late winter of 2010 I had the regular flu shot and then the H1N1 shot about two days later. I normally wouldn't hav

<span style='color: #808080;'><b>Describe Your Guillain-Barre syndrome from INFLUENZA (SEASONAL) (FLUARIX) 2009 Experience Here: </b> <strong></strong><span style='color: #808080;'>To whom ever it may

<span style='color: #808080;'><b>Describe Your Henoch-Schonlein purpura from INFLUENZA (H1N1) (H1N1 (MONOVALENT) SANOFI) 2010 Experience Here:</b> Vicious headaches, rash on legs and trunk, transient, cystitis type fee

<span style='color: #808080;'><b>Describe Your Incorrect route of drug administration from INFLUENZA (SEASONAL) (FLUARIX) 2010 Experience Here:</b> as of 3/2711 still have pain wondering of it caused a frozen shoulder

<span style='color: #808080;'><b>Describe Your Injection site swelling from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: I am 46, Female on discharge from hospital 12.6.10 10pm after treatment for acute diverticuli

<span style='color: #808080;'><b>Describe Your Neck pain from INFLUENZA (SEASONAL) (NO BRAND NAME) 2010 Experience Here:</b> Took 2010 flu shot on January 5, 2010. Fever ,chills and shaking 5 hours later. 12 hours late

<span style='color: #808080;'><b>Describe Your Pericarditis from INFLUENZA (H1N1) (H1N1 (MONOVALENT) (UNKNOWN)) 2010 Experience Here: Received H1N1 vaccine mid October 2009. Three weeks later diagnosed with accute paricarditis. My age is

<span style='color: #808080;'><strong>Describe Your Drug exposure during pregnancy from INFLUENZA (SEASONAL) (FLUZONE) 2010 Experience Here:</strong> <span style='color: #000000;'><span style=

I was diagnosed with influenza and treated with Tamilflu. I am also a diabetic, Tamiflu worked well for the influenza but it wreaked havoc on my diabetis. Extremely high sugar!!! There has got to be something else.

Is there such a thing as muscular Influenza and if so how long does it tend to last?

INFLUENZA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Conditions: Cancer;   Influenza Viral Infections
Interventions: Biological: Standard Trivalent Influenza Vaccine;   Biological: High-Dose Influenza Vaccine
Outcome Measures: The Geometric Mean Titer (GMT) of high-dose Influenza vaccine vs the standard trivalent Influenza vaccine in adult subjects on chemotherapy who are less than 65 years old.;   The seroprotection rate of high-dose Influenza vaccine vs standard trivalent Influenza vaccine in adult subjects on chemotherapy less than 65 years old.;   The seroconversion rate of high-dose Influenza vaccine versus standard trivalent Influenza vaccine in adult subjects on chemotherapy less than 65 years old.;   Evaluate and compare the local and systemic adverse events to both vaccines.
2 Recruiting Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting
Condition: Influenza
Interventions: Biological: High Dose Inactivated Influenza Vaccine;   Biological: Standard Dose Inactivated Influenza Vaccine
Outcome Measures: Non-inferiority of high-dose inactivated Influenza vaccine(HDIV) versus standard dose inactivated Influenza vaccine(SDIV) among residents of long term care(LTC) settings;   Non-inferiority and immunoprotection persistence at 6 months and the impact of potential immune modulators on titer response
3 Recruiting Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Condition: Influenza Virus
Interventions: Biological: Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV);   Biological: Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Outcome Measures: RT-PCR-confirmed Influenza cases in all subjects;   Percentage of subjects with solicited AEs;   Percentage of subjects with all unsolicited AEs;   Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, new onset of chronic disease, Adverse Event of Special Interest (AESI) and all medications associated;   Hazard ratios calculated: Occurrence of RT-PCR and culture-confirmed Influenza cases in all subjects;   Hazard ratios calculated: Early occurrence of RT-PCR-confirmed Influenza cases in all subjects;   Geometric mean HI titer (GMT);   Geometric mean ratio (GMR);   Percentage of vaccine naïve and non-naïve subjects achieving seroconversion;   Percentage of subjects with HI titer ≥ 1:40;   Percentage of subjects with higher HI titer thresholds;   Percentage of subjects with SAEs, AEs leading to withdrawal from the study or study vaccination, New Onset of Chronic Disease (NOCD), Adverse Events of Special Interest(AESI) and all medications associated
4 Recruiting Evaluate Reactogenicity and Immunogenicity of Standard-dose (SD) Versus High-dose (HD) Inactivated Influenza Vaccine Trivalent (IIV3) in Recipients of Solid Organ Transplants.
Conditions: Influenza, Human;   Transplantation Infection
Interventions: Biological: Influenza trivalent inactive vaccine;   Biological: Influenza trivalent inactive vaccine high dose
Outcome Measures: Number of patients with local or systemic reactions;   Measurement of strain-specific hemagglutination inhibition (HI) antibody titers;   All cause hospitalization;   All cause ED visits/unscheduled clinic visits;   Evaluate seroconversion and seroprotection rates
5 Unknown  FluMist in Egg Allergic Patients
Conditions: Egg Allergy;   Eligible for Vaccination Against Influenza
Interventions: Biological: FluMist intranasal Influenza vaccine;   Biological: Intramuscular Influenza injection ("flu shot")
Outcome Measures: To estimate the safety of LAIV in egg-allergic patients receiving the LAIV.;   To estimate the safety of a single, full-strength dose of TIV in egg allergic patients.
6 Unknown  Seasonal Influenza Vaccine Effectiveness Study in Kenya
Conditions: Influenza;   Influenza Like Illness;   Severe Acute Respiratory Illness
Intervention: Biological: Seasonal Influenza vaccine
Outcome Measures: Laboratory-confirmed Influenza infection;   Medically attended Influenza Like Illness(ILI) and Severe Acute Respiratory Illness (SARI);   Community-reported ILI SARI;   Laboratory-confirmed Influenza, medically attended ILI and SARI, and community-reported ILI and SARI in non-immunized household members
7 Recruiting The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis
Conditions: Immunogenicity and Adverse Drug Effect of Vaccines Influenza;   Chronic Kidney Disease
Intervention: Biological: Seasonal Influenza vaccine (AdimFlu-S)
Outcome Measures: The dynamic change of seroprotection rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.;   The safety of the Influenza vaccination in patients with chronic kidney disease.;   The dynamic change of seroconversion rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.;   The dynamic change of seroresponse rate related to administration of Influenza virus vaccine strains (2013-2014 season) of the AdimFlu-S manufactured by Adimmune Corporation.
8 Unknown  Two-site Intradermal Influenza Vaccination in Elderly
Condition: Influenza
Intervention: Biological: seasonal Influenza vaccine
Outcome Measures: immunogenicity;   comparison of the immunogenicity;   safety
9 Recruiting An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
Condition: Influenza
Interventions: Biological: Influenza vaccine GSK2321138A;   Biological: Havrix Junior;   Biological: Prevenar 13;   Biological: Varivax/ProVarivax;   Biological: Varilrix
Outcome Measures: First occurrence of Reverse transcription polymerase chain reaction (RT-PCR) confirmed moderate to severe Influenza A and/or B disease due to any seasonal Influenza strain;   First occurrence of RT-PCR confirmed Influenza A and/or B disease of any severity due to any seasonal Influenza strain;   First occurrence of Lower respiratory illness (LRI) with RT-PCR confirmed Influenza A and/or B infection due to any seasonal Influenza strain identified at any time starting 7 days before the onset of LRI and ending 7 days after end of LRI;   First occurrence of culture-confirmed moderate to severe Influenza A and/or B disease due to antigenically-matching Influenza strains;   First occurrence of culture-confirmed Influenza A and/or B disease of any severity due to antigenically-matching Influenza strains;   First occurrence of culture-confirmed moderate to severe Influenza A and/or B disease due to any seasonal Influenza strain;   First occurrence of culture-confirmed Influenza A and/or B disease of any severity due to any seasonal Influenza strain;   First occurrence of acute otitis media (AOM) with RT-PCR confirmed Influenza A and/or B infection due to any seasonal Influenza strain identified at any time starting 7 days before the onset of AOM and ending 7 days after end of AOM;   First occurrence of RT-PCR confirmed severe Influenza A and/or B due to any seasonal Influenza strain;   Humoral immune response in terms of haemagglutination-inhibition (HI) antibody titres against each of four vaccine strains contained in the FLU D-QIV (in immuno subcohort of subjects only);   Solicited local and general symptoms;   Unsolicited adverse events (AEs);   AEs with medically attended visits (MAV);   Serious Adverse events (SAEs);   Potential Immune-Mediated-Diseases (pIMDs)
10 Recruiting Influenza Immunization of Children in India
Condition: Influenza
Interventions: Biological: Inactivated Trivalent Influenza Vaccine (TIV);   Biological: Inactivated poliovirus vaccine (IPV), trivalent
Outcome Measures: Laboratory-confirmed Influenza infection in vaccinated child;   Laboratory-confirmed Influenza infection in household member of a vaccinated child.
11 Recruiting Field Trial of Maternal Influenza Immunization in Asia
Condition: Influenza Human
Interventions: Biological: Influenza vaccine;   Biological: saline placebo
Outcome Measures: Field Trial of Maternal Influenza Immunization;   Substudy #1: Transplacental Transfer of Influenza Antibody from Mother to Infant;   Substudy #2: Indirect Protection of Maternal Influenza Vaccination on Family Members;   Substudy #3: Hepatitis E Infection in Pregnancy;   Pertussis In Infants
12 Not yet recruiting Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults
Condition: Influenza
Interventions: Biological: Trivalent virosomal Influenza vaccine;   Biological: Commercial vaccine 1;   Biological: Quadrivalent virosomal Influenza vaccine;   Biological: Commercial vaccine 2
Outcome Measures: Number of participants with Solicited Local Adverse Events (AEs);   Number of participants with Solicited Systemic Adverse Events (AEs);   Number of participants with Unsolicited Adverse Events (AEs);   Number of participants with Serious Adverse Events (SAEs);   Number of Participants with Seroconversion;   Number of Participants with Seroprotection;   Change From Baseline in Geometric Mean Titer (GMT) of HI antibodies
13 Unknown  Evaluation of an Influenza Vaccination Implementation Strategy for Hospital Health Care Workers
Condition: Influenza
Intervention: Behavioral: Influenza vaccination implementation strategy
Outcome Measures: Influenza vaccine uptake among health care workers in the UMCs;   Absenteeism among health care workers during Influenza epidemics;   Patient morbidity and mortality
14 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine (no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
Outcome Measure: To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated)
15 Unknown  The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
Condition: Influenza
Interventions: Biological: Influenza Virus Vaccine(no Preservative );   Biological: Influenza Virus Vaccine(contains Preservative)
Outcome Measure: To evaluate the safety and the immunogenicity of Influenza Virus Vaccine (Split Virion, Inactivated) (Children Forms of Drug)
16 Unknown  Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
Condition: Influenza
Intervention: Biological: 2012 trivalent Influenza vaccine
Outcome Measures: Immunogenicity;   Safety;   Seasonal Influenza immunogenicity
17 Recruiting Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults
Condition: Influenza
Intervention:
Outcome Measure: Estimate the burden of Influenza disease and Influenza vaccine effectiveness.
18 Recruiting Optimizing Influenza Vaccination in Surgical Oncology Patients
Condition: Influenza
Intervention: Biological: Influenza vaccine
Outcome Measures: Antibody Titer;   Influenza-Like-Illness;   Surgical complications
19 Unknown  Rapid Flu Tests in Travelers With Fever
Condition: Influenza
Interventions: Device: BD Directigen EZ Flu A+B;   Other: Control
Outcome Measure: Difference in utilization of diagnostic tests and anti-infective drugs between the group with rapid flu test and the group without flu test
20 Not yet recruiting Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada
Condition: Influenza
Intervention:
Outcome Measures: Age-adjusted incidence rates of hospitalization and death occurring within 1 month of the diagnosis of Influenza;   Annual incidence rates of Influenza A and B cases;   Annual incidence rates of Influenza A and B cases among certain subsets of the population;   Visits to health care provider within 6 months of the diagnosis of Influenza